Proteon Pharmaceuticals, a company based in Poland that is committed to reducing the unnecessary use of antibiotics raised 21 million from investors to accelerate the commercialization of its products. The company has already produced bacteriophage-based products for aquaculture and livestock, believing that phage will help to reduce the need of using antibiotics. According to the company's website, all of its products follow the standards set by the European Union regulatory authorities. Also, the company takes credit for pioneering a bacteriophage dossier for a feed additive and has received the first-ever approval of quantitative methodologies from the European Reference Laboratory for the use of bacteriophages.
 |
| Poultry Photo credit Proteon |
The financing round was led by Nutreco, Aqua-Spark, and PFR Life Science, a portfolio company of the Polish Development Fund (PFR). Other investors in the round included Montis Capital, Seventure Partners as well as a group of Angel investors. The company believes that the fund raised will help in reducing the need for using antibiotics in livestock farming as well as promoting sustainable protein production for better human health. The funding will also help the company to reach the global livestock and aquaculture market with the same target of reducing the unnecessary use of antibiotics.
Proteon Pharmaceuticals has developed bacteriophage cocktails that address Salmonella and Avian Pathogenic E. Coli infections in poultry production as well as Pseudomonas and Aeromonas infection in aquaculture. The company’s products are registered and commercially available in selected markets throughout Southeast Asia, South America, and Africa.
Proteon Pharmaceuticals’ product development pipeline includes solutions for Mastitis in dairy cows and prevention of acute hepatopancreatic necrosis disease (AHPND) in shrimp production. The products are built using natural bacteriophages in cocktails that are precision-designed using an AI-supported platform technology